Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

This is a Phase 2 open-label extension (OLE) study to evaluate the long-term safety, tolerability, efficacy, pharmacokinetics, and the pharmacodynamics (PD) through potential exploratory biomarker(s) of intravenous (IV) WVE-N531 in patients with DMD who participated in another study of WVE-N531. All patients will have rolled over from a previous study of WVE-N531.

NCT Number	NCT07209332
Lead Sponsor	Wave Life Sciences Ltd.
Conditions	Duchenne Muscular Dystrophy
Enrollment	175 participants
Start Date	2025-12-28
Primary Completion	2029-03 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-06